Floatz logo

TAMOXIFEN

TAR-DNA-binding Protein-43

Taipei Medical University Shuang Ho HospitalSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the TAR-DNA-binding Protein-43 cohort.

Asset / SponsorPhaseRating
Rotigotine
I.R.C.C.S. Fondazione Santa Lucia
Phase 2B
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 2B
[18F]ACI-19626
AC Immune SA
Early Phase 1C

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →